127 related articles for article (PubMed ID: 9922713)
21. A HMG-CoA reductase inhibitor possesses a potent anti-atherosclerotic effect other than serum lipid lowering effects--the relevance of endothelial nitric oxide synthase and superoxide anion scavenging action.
Sumi D; Hayashi T; Thakur NK; Jayachandran M; Asai Y; Kano H; Matsui H; Iguchi A
Atherosclerosis; 2001 Apr; 155(2):347-57. PubMed ID: 11254905
[TBL] [Abstract][Full Text] [Related]
22. Differential effect of LFA703, pravastatin, and fluvastatin on production of IL-18 and expression of ICAM-1 and CD40 in human monocytes.
Takahashi HK; Mori S; Iwagaki H; Yoshino T; Tanaka N; Weitz-Schmidt G; Nishibori M
J Leukoc Biol; 2005 Mar; 77(3):400-7. PubMed ID: 15618295
[TBL] [Abstract][Full Text] [Related]
23. Fluvastatin depresses the enhanced lipid peroxidation in vitamin E-deficient hamsters.
Suzumura K; Ohashi N; Oka K; Yasuhara M; Narita H
Free Radic Res; 2001 Dec; 35(6):815-23. PubMed ID: 11811532
[TBL] [Abstract][Full Text] [Related]
24. Effect of fluvastatin and pravastatin, HMG-CoA reductase inhibitors, on fluconazole activity against Candida albicans.
Nash JD; Burgess DS; Talbert RL
J Med Microbiol; 2002 Feb; 51(2):105-109. PubMed ID: 11863260
[TBL] [Abstract][Full Text] [Related]
25. Fluvastatin, an HMG-CoA reductase inhibitor, protects LDL from oxidative modification in hypercholesterolemic rabbits.
Yasuhara M; Suzumura K; Tanaka K; Takahashi M; Aoki S; Odawara A; Narita H; Suzuki T
Biol Pharm Bull; 2000 May; 23(5):570-4. PubMed ID: 10823666
[TBL] [Abstract][Full Text] [Related]
26. Roles of different CYP enzymes in the formation of specific fluvastatin metabolites by human liver microsomes.
Toda T; Eliasson E; Ask B; Inotsume N; Rane A
Basic Clin Pharmacol Toxicol; 2009 Nov; 105(5):327-32. PubMed ID: 19663817
[TBL] [Abstract][Full Text] [Related]
27. Anti-oxidative properties of fluvastatin, an HMG-CoA reductase inhibitor, contribute to prevention of atherosclerosis in cholesterol-fed rabbits.
Rikitake Y; Kawashima S; Takeshita S; Yamashita T; Azumi H; Yasuhara M; Nishi H; Inoue N; Yokoyama M
Atherosclerosis; 2001 Jan; 154(1):87-96. PubMed ID: 11137086
[TBL] [Abstract][Full Text] [Related]
28. Species differences in the inhibiting effect of fluvastatin, a new inhibitor of HMG-CoA reductase, on cholesterol biosynthesis.
Yamamoto A; Itoh S; Hoshi K; Ichihara K
Res Commun Mol Pathol Pharmacol; 1994 Dec; 86(3):325-34. PubMed ID: 7712108
[TBL] [Abstract][Full Text] [Related]
29. Early administration of fluvastatin, but not at the onset of ischemia or reperfusion, attenuates myocardial ischemia-reperfusion injury through the nitric oxide pathway rather than its antioxidant property.
Matsuki A; Igawa A; Nozawa T; Nakadate T; Igarashi N; Nonomura M; Inoue H
Circ J; 2006 Dec; 70(12):1643-9. PubMed ID: 17127814
[TBL] [Abstract][Full Text] [Related]
30. HMG-CoA reductase activity in human liver microsomes: comparative inhibition by statins.
Dansette PM; Jaoen M; Pons C
Exp Toxicol Pathol; 2000 May; 52(2):145-8. PubMed ID: 10965989
[TBL] [Abstract][Full Text] [Related]
31. Sterol regulatory element binding protein-mediated effect of fluvastatin on cytosolic 3-hydroxy-3-methylglutaryl-coenzyme A synthase transcription.
Mascaró C; Ortiz JA; Ramos MM; Haro D; Hegardt FG
Arch Biochem Biophys; 2000 Feb; 374(2):286-92. PubMed ID: 10666309
[TBL] [Abstract][Full Text] [Related]
32. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences.
Lennernäs H; Fager G
Clin Pharmacokinet; 1997 May; 32(5):403-25. PubMed ID: 9160173
[TBL] [Abstract][Full Text] [Related]
33. Peroxynitrite-mediated oxidative modification of low-density lipoprotein by aqueous extracts of cigarette smoke and the preventive effect of fluvastatin.
Yamaguchi Y; Matsuno S; Kagota S; Haginaka J; Kunitomo M
Atherosclerosis; 2004 Feb; 172(2):259-65. PubMed ID: 15019535
[TBL] [Abstract][Full Text] [Related]
34. Fluvastatin induces apoptosis in rat neonatal cardiac myocytes: a possible mechanism of statin-attenuated cardiac hypertrophy.
Ogata Y; Takahashi M; Takeuchi K; Ueno S; Mano H; Ookawara S; Kobayashi E; Ikeda U; Shimada K
J Cardiovasc Pharmacol; 2002 Dec; 40(6):907-15. PubMed ID: 12451324
[TBL] [Abstract][Full Text] [Related]
35. HMG-CoA reductase inhibitor fluvastatin prevents angiotensin II-induced cardiac hypertrophy via Rho kinase and inhibition of cyclin D1.
Morikawa-Futamatsu K; Adachi S; Maejima Y; Tamamori-Adachi M; Suzuki J; Kitajima S; Ito H; Isobe M
Life Sci; 2006 Aug; 79(14):1380-90. PubMed ID: 16712874
[TBL] [Abstract][Full Text] [Related]
36. Fluvastatin reduces modification of low-density lipoprotein in hyperlipidemic rabbit loaded with oxidative stress.
Yamaguchi Y; Matsuno S; Kagota S; Haginaka J; Kunitomo M
Eur J Pharmacol; 2002 Feb; 436(1-2):97-105. PubMed ID: 11834252
[TBL] [Abstract][Full Text] [Related]
37. Effects of fluvastatin and its major metabolites on low-density lipoprotein oxidation and cholesterol esterification in macrophages.
Tanaka K; Yasuhara M; Suzumura K; Narita H; Suzuki T
Jpn J Pharmacol; 2001 Jul; 86(3):289-96. PubMed ID: 11488428
[TBL] [Abstract][Full Text] [Related]
38. 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors reduce human pancreatic cancer cell invasion and metastasis.
Kusama T; Mukai M; Iwasaki T; Tatsuta M; Matsumoto Y; Akedo H; Inoue M; Nakamura H
Gastroenterology; 2002 Feb; 122(2):308-17. PubMed ID: 11832446
[TBL] [Abstract][Full Text] [Related]
39. Fluvastatin reduced liver injury in rat model of extrahepatic cholestasis.
Demirbilek S; Tas E; Gurunluoglu K; Akin M; Aksoy RT; Emre MH; Aydin NE; Ay S; Ozatay N
Pediatr Surg Int; 2007 Feb; 23(2):155-62. PubMed ID: 17086424
[TBL] [Abstract][Full Text] [Related]
40. Additive antioxidative effect of hormone replacement therapy combined with a statin.
Seeger H; Wallwiener D; Mueck AO
Clin Exp Obstet Gynecol; 2000; 27(3-4):179-81. PubMed ID: 11214944
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
